vs
EXACT SCIENCES CORP（EXAS）与微博公司（WB）财务数据对比。点击上方公司名可切换其他公司
微博公司的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），微博公司净利率更高（35.7% vs -9.8%，领先45.5%），过去两年微博公司的营收复合增速更高（22.6% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
微博公司是中国知名的社交网络企业，旗下运营的新浪微博是国内极具影响力的微博客平台，公司总部位于中国北京，为数以亿计的用户提供社交互动、资讯传播、内容创作等多元互联网服务。
EXAS vs WB — 直观对比
营收规模更大
WB
是对方的1.5倍
$878.4M
净利率更高
WB
高出45.5%
-9.8%
两年增速更快
WB
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | $458.3M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 29.1% |
| 净利率 | -9.8% | 35.7% |
| 营收同比 | 23.1% | — |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASWB
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $1.3B | ||
| Q2 25 | $811.1M | $841.7M | ||
| Q1 25 | $706.8M | $396.9M | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | $1.3B | ||
| Q2 24 | $699.3M | $833.4M | ||
| Q1 24 | $637.5M | $395.5M |
净利润EXASWB
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $458.3M | ||
| Q2 25 | $-1.2M | $234.8M | ||
| Q1 25 | $-101.2M | $108.1M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $297.4M | ||
| Q2 24 | $-15.8M | $164.6M | ||
| Q1 24 | $-110.2M | $51.1M |
毛利率EXASWB
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASWB
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | 29.1% | ||
| Q2 25 | -0.3% | 30.4% | ||
| Q1 25 | -13.6% | 27.8% | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | 29.0% | ||
| Q2 24 | -3.8% | 28.2% | ||
| Q1 24 | -16.7% | 25.2% |
净利率EXASWB
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 35.7% | ||
| Q2 25 | -0.1% | 27.9% | ||
| Q1 25 | -14.3% | 27.2% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 22.9% | ||
| Q2 24 | -2.3% | 19.8% | ||
| Q1 24 | -17.3% | 12.9% |
每股收益（稀释后）EXASWB
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.9B |
| 总资产 | $5.9B | $6.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASWB
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $858.4M | $1.2B | ||
| Q1 25 | $786.2M | $1.2B | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | $1.9B | ||
| Q1 24 | $652.1M | $2.1B |
股东权益EXASWB
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $3.9B | ||
| Q2 25 | $2.5B | $3.6B | ||
| Q1 25 | $2.4B | $3.5B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | $3.4B | ||
| Q1 24 | $3.1B | $3.3B |
总资产EXASWB
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $6.9B | ||
| Q2 25 | $5.8B | $6.5B | ||
| Q1 25 | $5.7B | $6.7B | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.7B | $7.1B | ||
| Q1 24 | $6.4B | $7.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASWB
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | — | ||
| Q2 24 | $107.1M | — | ||
| Q1 24 | $-82.3M | — |
自由现金流EXASWB
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASWB
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASWB
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
